Nephrotic Syndrome
Conditions
Brief summary
The purpose of this study is to investigate if lymphocyte markers predict response to rituximab among patients with idiopathic nephrotic syndrome
Interventions
DRUGRituximab
Sponsors
National University Health System, Singapore
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 1-18 years old at the time of diagnosis of nephrotic syndrome * Steroid-dependent (SDNS) or steroid-resistant nephrotic syndrome (SDNS)
Exclusion criteria
* eGFR \<60 ml/min per 1.73m2 * infantile onset of nephrotic syndrome * nephrotic syndrome secondary to chronic infections such as hepatitis B, hepatitis C or human immunodeficiency virus, systemic lupus erythematosus, Henoch-Schönlein purpura, IgA nephropathy, membranoproliferative glomerulonephritis or membranous nephropathy * current or previous therapy for tuberculosis * presence of mutations in WT1, NPHS1, NPHS2 and TRPC6.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response | 3 months | Resolution of proteinuria (urine protein:creatinine \<0.02 g/mmol or urine protein excretion \<0.3 g/1.73m2/day) and ability to wean off prednisolone and calcineurin inhibitor at three months after the last dose of rituximab. |
Countries
Singapore
Contacts
Primary ContactHui-Kim Yap
Outcome results
None listed